Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 2, February, p. 199–202

doi: 10.17219/acem/78592

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The role of OPRM1 polymorphism in the etiology of alcoholism

Agnieszka Samochowiec1,A,B,C,D,E,F, Jerzy Samochowiec2,A,B,C,D,E,F, Justyna Pełka-Wysiecka2,B, Jolanta Kucharska-Mazur2,B, Elżbieta Grochans3,C, Marcin Jabłoński2,B, Przemysław Bieńkowski4,C, Sławomir Murawiec5,C, Iwona Małecka2,B, Monika Mak2,C, Łukasz Kołodziej6,B,C, Janusz Heitzman7,E, Anna Grzywacz2,A,B,C,D,E

1 Department of Clinical Psychology, Institute of Psychology, University of Szczecin, Poland

2 Department of Psychiatry, Faculty of Medicine, Pomeranian Medical University in Szczecin, Poland

3 Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, Poland

4 Department of Psychiatry, Faculty of Health Sciences, Medical University of Warsaw, Poland

5 DIALOG Therapy Center, Warszawa, Poland

6 Department of Orthopedics, Faculty of Medicine, Pomeranian Medical University in Szczecin, Poland

7 Department of Forensic Psychiatry, Institute of Psychiatry and Neurology, Warszawa, Poland

Abstract

Background. Numerous studies have investigated the association between the OPRM1 A118G polymorphism (rs1799971) and alcohol dependence, but the results have been inconsistent. The endogenous opioid system has been implicated in the development of alcohol dependence for its prominent role in the central rewarding mechanism.
Objectives. The aim of this study was to evaluate the role of the A118G polymorphism of the OPRM1 gene in the pathogenesis of alcohol dependence syndrome (ADS).
Material and Methods. The OPRM1 (rs1799971) polymorphism was investigated in an association study of a group of ADS patients (n = 177) and in subgroups (delirium tremens and/or seizures, age at onset <26 years, dissocial alcoholics, positive familial history of alcoholism, delirium tremens, and seizures). The control group consisted of healthy volunteers, with matched gender and age, and with psychiatric disorders excluded (n = 162).
Results. Our research shows that there are differences in the genotypes and alleles of the OPRM1 polymorphism in the case-control study. Furthermore, we observed associations in our homogeneous subgroups – in the group of patients with ADS and accompanying delirium tremens and/or seizures at the genotype level, as well as in the subgroup of patients under 26 years of age with an early onset of dependence.
Conclusion. It is strongly possible that the G allele described in numerous studies can be associated with a response to treatment, but not typology, or the very predisposition toward alcoholism. It is necessary to carry out further research which would embrace a larger group of patients; it should be divided into other homogeneous subgroups, including, e.g., naltrexone pharmacotherapy.

Key words

alcohol dependence, OPRM1 gene, opioid system

References (20)

  1. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res. 1975;88 (2):295–308.
  2. Terenius L, Wahlström A. Search for an endogenous ligand for the opiate receptor. Acta Physiol Scand. 1975;94(1):74–81.
  3. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530–534.
  4. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. Arch Gen Psychiatry. 2007;64(9):1069–1077.
  5. Kiefer F, Horntrich M, Jahn H, Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on β-endorphin deficiency? Psychopharmacology (Berl). 2002;162(4):433–437.
  6. Agabio R, Colombo G. GABAB receptor as therapeutic target for drug addiction: From baclofen to positive allosteric modulators [in Polish]. Psychiatr Pol. 2015;49(2):215–223.
  7. Iwanicka KA, Olajossy M. The concept of alcohol craving [in Polish]. Psychiatr Pol. 2015;49(2):295–304.
  8. Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav. 2004;81(2):339–358.
  9. Kiejna A, Piotrowski P, Adamowski T, et al. The prevalence of common mental disorders in the population of adult Poles by sex and age structure – an EZOP Poland study [in Polish]. Psychiatr Pol. 2015;49(1):15–27.
  10. Klimkiewicz A, Klimkiewicz J, Jakubczyk A, Kieres-Salomoński I, Wojnar M. Comorbidity of alcohol dependence with other psychiatric disorders. Part I. Epidemiology of dual diagnosis [in Polish]. Psychiatr Pol. 2015;49(2):265–275.
  11. Klimkiewicz A, Klimkiewicz J, Jakubczyk A, Kieres-Salomoński I, Wojnar M. Comorbidity of alcohol dependence with other psychiatric disorders. Part II. Pathogenesis and treatment [in Polish]. Psychiatr Pol. 2015;49(2):277–294.
  12. O’Brien CP. Research advances in the understanding and treatment of addiction. Am J Addict. 2003;12(Suppl 2):S36–47.
  13. Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry. 2008;65(2):135–144.
  14. Van den Wildenberg E, Wiers RW, Dessers J, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue--induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res. 2007;1:1–10.
  15. Anton R, Oroszi G, O’Malley S, Couper D, Swift R. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry. 2008;65(2): 135–144.
  16. Miranda R, Ray L, Justus A, et al. Initial evidence of an association between OPRM1 and adolescent alcohol misuse. Alcohol Clin Exp Res. 2010;34:112–122.
  17. Chen D, Liu L, Xiao Y, Peng Y, Yang C, Wang Z. Ethnic-specific meta-analyses of association between the OPRM1 A118G polymorphism and alcohol dependence among Asians and Caucasians. Drug Alcohol Depend. 2012;123(1–3):1–6.
  18. Bart G, Kreek MJ, Ott J, et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology. 2005;30(2):417–422.
  19. Rommelspacher H, Smolka, M, Samochowiec J, Hoehe MR. Genetic analysis of the m-opioid receptor in alcohol-dependent individuals. Alcohol. 2001;24(2):129–135.
  20. Bieńkowski P. Pharmacological features of naltrexone and its use in the treatment of alcohol dependence [in Polish]. Psychiatr Pol. 2013;47(1):117–126.